Publications
Drug Information Group faculty regularly publish articles on a variety of topics in peer-reviewed journals and other educational formats.
Recent Publications (2013 - Present) Heading link
- Fydrych J, Ipema H, Munir F, Koppen L. Updated survey of drug information curricula and instructional methods among US colleges of pharmacy. Am J Pharm Educ. Under review.
- Qualls DA, Lambert N, Caimi PF, Merrill M, Pullarkat P, Godby RC, Bond DA, Wehmeyer GT, Romancik J, Amoozgar B, Leslie L, Natoupil LJ, Crombie JL, Abramson JS, Khurana A, Nowakowski GS, Maddocks K, Rutherford SC, Kahl B, Okwali M, Buege MJ, Seshan V, Batlevi CL, Salles G. Tafasitamab and lenalidomide in large B cell lymphoma: real-world outcomes in a multicenter retrospective study. Blood. 2023; in press.
- Rodriguez R, Joseph H, Macrito R, Lee TA, Sweiss K. Risk prediction models for antineoplastic-associated cardiotoxicity in treatment of breast cancer: A systematic review. Am J Health Syst Pharm. 2023;zxad147. doi:10.1093/ajhp/zxad147
- Griggs L, Phillips J. Drug allergy practice parameter update: focus on antibiotics. KeePosted. 2023;49(3):26-29.
- Phillips J. Medical misinformation: the power of influence. J Am Coll Clin Pharm. 2023;6(5):444-445.
- Sawalha Y, Goyal S, Switchenko JM, Romancik JT, Kamdar M, Greenwell IB, Hess BT, Isaac KM, Portell CA, Mejia Garcia A, Goldsmith S, Grover NS, Riedell PA, Karmali R, Burkart M, Buege, Akhtar O, Torka P, Kumar A, Hill BT, Kahl BS, Cohen JB. A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Adv. 2023;7(13):2983-2993.
- Buege MJ, Drill E, Horwitz SM, LeVoir A, Pak T, Peterson TJ, Dao PH, Matasar MJ. Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure. Eur J Haematol. 2023;111(1):96-102.
- Villa D, Jiang A, Visco C, Crosbie N, McCulloch R, Buege MJ, Kumar A, Bond DA, Paludo J, Maurer MJ, Thanarajasingam G, Lewis KL, Cheah CY, Baech J, El-Galaly TC, Kugathasan L, Scott DW, Gerrie AS, Lewis D.. Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma. Blood Adv. 2023;7(16):4576-4585.
- Elste J, Ipema H, Denton C, Munir F, et al. Light-sensitive injectable prescription drugs – 2022. Hosp Pharm. 2023;58(5):448-475.
- Ipema HJ, Elste J, Koppen L, Soni R, et al. Inclusion of optimal guidelines for pharmacists in UpToDate. Ann Pharmacother. 2022;56(9):1084-1085.
- King A, Land J, Liu D, Peterson T, Reiss S, Vadakkel G, Eng S, Pak T, Daukshus N, Spatz K, LeVoir A, Buege M, Weis T, Gutierrez J. Cancer pharmacology. In: Choudhury N, Murciano-Goroff Y, Drilon A, Vasan N, eds. Pocket Oncology. 3rd Wolters Kluwer: Philadelphia, PA. 2022;66-118.
- Rodriguez R, Brunner R, Spencer S, et al. Time to inclusion in clinical guidance documents for non-oncological orphan drugs and biologics with expedited FDA designations: a retrospective survival analysis. BMJ Open. 2021;11(12):e057744.
- Brunner R, Gerberich A. Managing Pain in Parkinson’s Disease. Practical Pain Management. 2021;21(1). Available at: https://www.practicalpainmanagement.com/treatments/pharmacological/managing-pain-parkinson-disease
- Gerberich A, Ipema HJ. A primer on ocular viscosurgical devices. Am J Health Syst Pharm. 2021;78(22):2020-2032.
- Joseph H, Gabay M. CDC Opioid Prescribing Guideline: Clinical Concerns Lead to Revision. Practical Pain Management. 2021;21(6). Available at: https://www.practicalpainmanagement.com/treatments/pharmacological/opioids/cdc-opioid-prescribing-guideline-clinical-concerns-lead-revision
- West-Thielke PM, Ipema HJ, Campbell-Lee S, et al. Removal of anti-thymocyte globulin by plasma exchange in ABO-incompatible and positive crossmatch kidney transplant recipients. Transplant Proc. 2021;53(5):1548-1553.
- Bursua A, Mudreac A, Koppen L, Larson C, Park YS, Sreedhar R. Effect of default order standardization on opioid prescribing patterns. Jt Comm J Qual Patient Saf. 2021;47(7):431-437.
- Sarna K. Best practices for monitoring hazardous drug surface contamination: a guidance for health care institutions. Pharmacy Practice News. July 23, 2020. Available at: https://www.pharmacypracticenews.com/Review-Articles/Article/07-20/Best-Practices-for-Monitoring-Hazardous-Drug-Surface-Contamination/58875
- Sarna K. Hyperkalemia management: role of the pharmacist in optimization of care. Pharmacy Practice News. March 19, 2020. Available at: https://www.pharmacypracticenews.com/Clinical/Article/03-20/Hyperkalemia-Management/57443
- Nathan J, Grossman S, Ness G, Gabay M, Ipema H, Tierno H. Update on the status of drug information centers in the United States. Am J Health Syst Pharm. 2020;77(1):33-38.
- Sarna KV, Griffin T, Tarlov E, Gerber BS, Gabay MP, Suda KJ. Trends in gender composition on editorial boards in leading medicine nursing, and pharmacy journals. J Am Pharm Assoc. 2020;60(4):565-570.
- Spencer SH, Menard SM, Labedz MZ, Krueger CD, Sarna KV. Enteral tube administration of oral chemotherapy drugs. J Oncol Pharm Pract. 2020;26(3):703-717.
- Ipema H, Zacher J, Galka E, Nazari J, Varabyeva A, Yu M, Hartke P. Drugs to be used with a filter for preparation and/or administration-2019. Hosp Pharm. 2021;56(2):81-87.
- Miles K, Zacher J. A physician primer: drugs with orphan designations for the treatment of pain conditions. Practical Pain Management. 2019. Available at: https://www.practicalpainmanagement.com/resources/practice-management/physician-primer-drugs-orphan-designations-treatment-pain-conditions?fbclid=IwAR00bFHTLtzYJvpnDRYaDA4H1TZC0Gota6X1Zf1pNmui04XB-POuOmBIaVg
- Gerberich A, Spencer S, Ipema H. National Guideline Clearinghouse is no more – keep calm and search on. Ann Pharmacother.2019;53(4):434-436.
- Rodriguez R, Koppen L, Patel YA, Ellinger, LK. Characteristics of shortage-related drug information requests and recommendations from a nationally-serving drug information center.Am J Health Syst Pharm. 2019;76(23):1900-1902.
- Sarna KV, Gross AE. Vancomycin versus metronidazole for non-severe Clostridioides difficile infection: are the data adequate to change practice? Ann Pharmacother. 2019;53(8):845-852.
- Rasmussen JT, Ipema HJ. Formulary considerations for insulins approved through the 505(b)(2) ‘follow-on’ pathway. Ann Pharmacother. 2019;53(2):204-210.
- Koppen L, Suda K, Rowan S, McGregor J, Evans C. Dentists’ prescribing of antibiotics and opioids to Medicare Part D beneficiaries: medications of high impact to public health. J Am Dent Assoc. 2018;149(8):721-730.
- Spencer S, Ipema H, Hartke P, Krueger C, Rodriguez R, Gross AE, Gabay M. Intravenous push administration for antibiotics: An alternative method. Hosp Pharm. 2018;53(3):157-169.
- Koppen L, Whitaker A, Rosene A, Beckett R. Effect of berberine alone and in combination for the treatment of hyperlipidemia: a systematic review. J Evid Based Complementary Altern Med. 2017;22(4):956-968.
- Rodriguez R, Soni R. Psoriatic arthritis: established, newer, and emerging therapies. Practical Pain Management. 2017;17(6). Available at: https://www.practicalpainmanagement.com/pain/myofascial/inflammatory-arthritis/psoriatic-arthritis-established-newer-emerging-therapies.
- Koppen L, Afanasjeva J. A brief history of the FDA’s role in the ongoing effort to ensure safe opioid use. Practical Pain Management. 2017;17(1). Available at: https://www.practicalpainmanagement.com/treatments/pharmacological/opioids/brief-history-fda-role-ongoing-effort-ensure-safe-opioid-use.
- Bursua A, Hartke PL, Larson CM. Benchmarking and medication error rates. Am J Health Syst Pharm. 2016;73(11):744.
- Hartke P, Afanasjeva J. Sports-related pain: topical treatments. Practical Pain Management. 2016;16(4). Available at: http://www.practicalpainmanagement.com/treatments/pharmacological/non-opioids/sports-related-pain-topical-treatments.
- Hartke PL, Vermeulen LC, Hoffman JM, et al. Accuracy of prescription drug expenditure forecasts published in the AJHP. Am J Health Syst Pharm. 2015;72(19):1642-1648.
- Koppen L, Phillips J, Papageorgiou R. Analysis of reference sources used in drug-related Wikipedia articles. J Med Libr Assoc. 2015;103(3):140-144.
- Zych K, Ipema H. Psoriasis and psoriatic arthritis: update in management. Specialty Pharmacy Continuum. January/February 2016. Available at: http://www.specialtypharmacycontinuum.com/download/psoriasis_spc0116_WM.pdf.
- Ghaibi S, Ipema HJ, Gabay MG. ASHP guideline on the pharmacist’s role in providing drug information. Am J Health Syst Pharm. 2015;72(7):573-577.
- Ipema HJ, Tanzi MG. Medical writing and peer review. In: Gabay M, ed. The Clinical Practice of Drug Information. 1st Sudbury (MA): Jones & Bartlett Learning; 2015.
- Krueger C. New treatments for rheumatoid arthritis. Specialty Pharmacy Continuum. 2014;4(3):8-10.
- Fisseha N, Rodriguez R, Ipema H. Olysio (simeprevir) Review. Illinois Pharmacist. 2014;26(2):26-27.
- UIC Drug Information Group. Light-sensitive injectable prescription drugs. Hosp Pharm. 2014;49(2):136-163.
- Stachnik JM, Krueger CD. Infertility in women. In: Murphy JE, Lee MW, eds. Pharmacotherapy Self-Assessment Program, 2013 Book 2. Special Populations. Lenexa, KS: American College of Clinical Pharmacy, 2013:61-76.
- Krueger C. Ask The Expert: I have recently read a lot on twitter that NSAIDs cause more deaths than opioids. Can you clarify if this is true? Practical Pain Management. 2013;13(10). Available at: http://www.practicalpainmanagement.com/treatments/pharmacological/opioids/ask-expert-do-nsaids-cause-more-deaths-opioids